Menu Search
Equities

Clinuvel Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
UR9:MUN

Clinuvel Pharmaceuticals Ltd

Actions
  • Price (EUR)6.59
  • Today's Change-0.225 / -3.30%
  • Shares traded750.00
  • 1 Year change-5.12%
  • Beta0.9348
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.

  • Revenue in AUD (TTM)95.02m
  • Net income in AUD36.17m
  • Incorporated1999
  • Employees16.00
  • Location
    Clinuvel Pharmaceuticals LtdLevel 22, 535 Bourke StreetMELBOURNE 3000AustraliaAUS
  • Phone+61 39660-4900
  • Fax+61 39660-4909
  • Websitehttps://www.clinuvel.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.